Business Description
Great Novel Therapeutics Biotech & Medicals
SIC : 8731
ISIN : TW0007427007
Total Employee Number:
22Description
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 108.62 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 92.33 | |||||
Beneish M-Score | -3.82 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.4 | |||||
3-Year EBITDA Growth Rate | -2.2 | |||||
3-Year EPS without NRI Growth Rate | 1.4 | |||||
3-Year FCF Growth Rate | 9.3 | |||||
3-Year Book Growth Rate | 3.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.29 | |||||
9-Day RSI | 51.36 | |||||
14-Day RSI | 53.07 | |||||
3-1 Month Momentum % | 75.34 | |||||
6-1 Month Momentum % | 125.28 | |||||
12-1 Month Momentum % | 145.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 26.62 | |||||
Quick Ratio | 26.27 | |||||
Cash Ratio | 25.68 | |||||
Days Inventory | 471.52 | |||||
Days Sales Outstanding | 72.26 | |||||
Days Payable | 369.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.3 | |||||
Shareholder Yield % | -7.74 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 18.72 | |||||
Operating Margin % | -1886.12 | |||||
Net Margin % | -1798.73 | |||||
EBITDA Margin % | -1687.48 | |||||
FCF Margin % | -1451.14 | |||||
OCF Margin % | -1416.3 | |||||
ROE % | -18.4 | |||||
ROA % | -17.65 | |||||
ROIC % | -175.88 | |||||
3-Year ROIIC % | 71.96 | |||||
ROC (Joel Greenblatt) % | -795.04 | |||||
ROCE % | -18.25 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 607.57 | |||||
PB Ratio | 5.07 | |||||
Price-to-Tangible-Book | 5.26 | |||||
EV-to-EBIT | -28.08 | |||||
EV-to-EBITDA | -29.9 | |||||
EV-to-Revenue | 504.71 | |||||
EV-to-FCF | -32.83 | |||||
Price-to-GF-Value | 0.67 | |||||
| Price-to-Net-Current-Asset-Value | 5.51 | |||||
| Price-to-Net-Cash | 5.72 | |||||
Earnings Yield (Greenblatt) % | -3.57 | |||||
FCF Yield % | -2.41 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Great Novel Therapeutics Biotech & Medicals Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 6.208 | ||
| EPS (TTM) (NT$) | -2.454 | ||
| Beta | 0.2952 | ||
| 3-Year Sharpe Ratio | 0.18 | ||
| 3-Year Sortino Ratio | 0.4 | ||
| Volatility % | 81.99 | ||
| 14-Day RSI | 53.07 | ||
| 14-Day ATR (NT$) | 2.976342 | ||
| 20-Day SMA (NT$) | 72.915 | ||
| 12-1 Month Momentum % | 145.03 | ||
| 52-Week Range (NT$) | 28.064786 - 82.8 | ||
| Shares Outstanding (Mil) | 52.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Great Novel Therapeutics Biotech & Medicals Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Great Novel Therapeutics Biotech & Medicals Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Great Novel Therapeutics Biotech & Medicals Frequently Asked Questions
What is Great Novel Therapeutics Biotech & Medicals(ROCO:7427)'s stock price today?
The current price of ROCO:7427 is NT$72.30. The 52 week high of ROCO:7427 is NT$82.80 and 52 week low is NT$28.06.
When is next earnings date of Great Novel Therapeutics Biotech & Medicals(ROCO:7427)?
The next earnings date of Great Novel Therapeutics Biotech & Medicals(ROCO:7427) is .
Does Great Novel Therapeutics Biotech & Medicals(ROCO:7427) pay dividends? If so, how much?
Great Novel Therapeutics Biotech & Medicals(ROCO:7427) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers